Coronavirus (2019-nCoV)

WHO recommends NaDCC Granules

5th February 2020


The 2019 novel coronavirus (2019-nCoV) outbreak is continuing to evolve with many cases having now been detected outside of Wuhan, China. As of February 4th, the World Health Organisation (WHO) have reported 425 deaths in China and 20,630 confirmed cases globally. A total of 159 cases have been identified outside of China, spread worldwide across 23 countries. There has been one recorded death outside of China.


As a result, the WHO have declared the 2019-nCoV outbreak a public health emergency of international concern (PHEIC). By declaring this outbreak a PHEIC, the WHO has highlighted the urgency and need for international efforts to minimize further spread. The aim of a PHEIC is to ensure a global response that is evidence-based, measured and balanced. The enhanced cooperation will increase transparency, the development of vaccines, diagnostics and therapeutics. For more information on the WHO’s response, please visit:


Although the WHO is still to determine the survival capabilities of 2019-nCoV on surfaces, preliminary information suggests the virus could survive for several hours. In the case of high touch surfaces which could harbour respiratory droplets from an infected patient, regular disinfection is necessary. Our surface disinfectant products are effective at killing this viral pathogen. The WHO have also recommended the use of NaDCC granules for the disinfection of healthcare facilities as part of their recommended Disease commodity package – Novel Coronavirus



C​andida auris

An Unusual Yeast Causing Serious Infection

C​andida auris – An Unusual Yeast Causing Serious Infection



Over the past number of years discussion surrounding Candida auris has continued to increase. This pathogen is regularly discussed by the media and governmental bodies. It is of high concern to healthcare facilities. But what is Candida auris and why is it gaining so much attention?


Candida auris is a fungal pathogen, to be more specific, it is a type of yeast. This pathogen was first reported in Japan in 2009 and has since been linked with healthcare associated infections (HAIs) on five continents (1). C. auris control is challenging due to the difficulty in identifying this pathogen in the clinical laboratory. Moreover, C. auris often exhibits high levels of multi drug resistance, leading to high rates of treatment failure with invasive infections (2). The United States Centers for Disease Control and Prevention (CDC) map new case reports worldwide (


As of January 31st, 2019, a total of 560 confirmed clinical cases have been identified in the U.S.

The most commonly observed invasive infection associated with C. auris has been blood stream infections, with mortality in the range of 30 to 60%. Patients involved generally have high healthcare exposure, however, infection may not be apparent until weeks after initial admission (2). The best treatment practice for C. auris infection has not been defined.

C. auris appears to spread via patients and the environment. It has be isolated from the skin of affected patients as well a patient contact areas, such as sinks, medical equipment, furniture and mattresses (3, 4). Recent investigations suggest quaternary ammonium compounds may not be effective against C. auris (5). The US CDC recommend that sporicidal disinfectants (those listed on the U.S. EPA List K) be used where C. auris is of concern and provide several other points of interest in relation to C. auris transmission control, such as hand hygiene and contact precautions (


There is still a lot to learn regarding this pathogen, such as its origin in the natural environment, the reason for its sudden emergence and high antifungal resistance. Healthcare workers should remain ever vigilant for C. auris where Candida spp. infection is suspected due to its impact on patient mortality. Undoubtedly control of these outbreaks will prove a challenge until more information about this unusual pathogen become available. Providing care in accordance with best practice outlined by the CDC will be key until more defined control mechanisms become apparent.



1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. Candida auris sp . nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol: 53:41–44

2. Spivak ES, Hanson E. 2018. Candida auris : an Emerging Fungal Pathogen. J. Clin. Microbiol. 56:1–10.

3. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J,Palmore TN, Zelzany A, Adams EH,Quinn M, Chaturvedi, S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J,Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2017. Investigation of the First Seven Reported Cases of Candida auris , a Globally Emerging Invasive Multidrug-Resistant Fungus — United States , May 2013 – August 2016. Amer. J. Transplant. 17:296-299

4.Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-james D, Fisher MC. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 5:35.

5. Cadnum JL, Shaikh AA, Christina T, Sankar T, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. 2017. Effectiveness of Disinfectants Against Candida auris and Other Candida Species. Infect. Control and Hosp. Emidemiol. 38:1–4.



Kersia Coronavirus Update